Home Featured Page 293

Featured

Latest

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

Introducing The Psychedelic News Feed Podcast

Field Notes #5: ‘Psychedelics Week’ in Washington D.C.

What Lynn Watkins Actually Told the FDA about Chronic Pain and Psychedelics

Beyond the Foxhole: How Psychedelic Policy’s Coalition Is Growing Past Veterans

Silo Wellness Hires Two Veterans of Lifestyle Marketing and Cannabis Industry...

Psyched Wellness Initiates Study on AME-1 Extract for Gut Health

MindMed Announces 2020 Year-End Financial Results; Current Cash Balance of $161...

Nova Mentis Announces Promising Research Results

MindMed Announces the Addition of Stanford University Neuroscientist as Chair of...

Horizons ETFs Completes Rebalance of World’s First Psychedelics ETF

Champignon Brands Announces Filing of Listing Statement

Psychedelic Bulletin: UW-Madison Launches Psychedelic Master’s Program; COMPASS Granted 2 Patents

Early Clinical Research History of DMT

EDITOR PICKS

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

Introducing The Psychedelic News Feed Podcast

Field Notes #5: ‘Psychedelics Week’ in Washington D.C.

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

Introducing The Psychedelic News Feed Podcast

Field Notes #5: ‘Psychedelics Week’ in Washington D.C.

What Lynn Watkins Actually Told the FDA about Chronic Pain and Psychedelics

Beyond the Foxhole: How Psychedelic Policy’s Coalition Is Growing Past Veterans

Silo Wellness Hires Two Veterans of Lifestyle Marketing and Cannabis Industry...

Psyched Wellness Initiates Study on AME-1 Extract for Gut Health

MindMed Announces 2020 Year-End Financial Results; Current Cash Balance of $161...

Senior Program Director

Nova Mentis Announces Promising Research Results

MindMed Announces the Addition of Stanford University Neuroscientist as Chair of...

Horizons ETFs Completes Rebalance of World’s First Psychedelics ETF

Champignon Brands Announces Filing of Listing Statement

Psychedelic Bulletin: UW-Madison Launches Psychedelic Master’s Program; COMPASS Granted 2 Patents

Early Clinical Research History of DMT

EDITOR PICKS

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

Introducing The Psychedelic News Feed Podcast

Field Notes #5: ‘Psychedelics Week’ in Washington D.C.

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY